Authors
Latest:
ACCP White Paper: Guidance on Natural ProductsACCP has updated its white paper on natural products, and published it in the January issue of the journal Pharmacotherapy.
Latest:
Shining Light into the DarknessAdvocacy group staffed by hepatitis C patients helps others find hope in fight against the disease.
Latest:
Incentive Formularies: Spending and Utilization for 3 Common Drug ClassesIncentive formularies with varying cost sharing led to modestly lower overall spending, with savings for plan sponsors offset by increased out-of-pocket spending.
Latest:
Patient Engagement and an Aging PopulationUnderstanding the needs of seniors with cancer and helping them to manage the complexities of the treatment process are essential to successful patient engagement and improved clinical outcomes.
Latest:
Tips for Finding the Perfect Residency MatchFor fourth-year residency candidates across the nation, January through March is often a whirlwind of presentations, program overviews, panels, and a plethora of questions.
Latest:
The Expanding Roles of Genetic Counselors in Specialty Pharmacy ManagementCurrently, genetic counselors apply their molecular and clinical expertise in diverse roles, many delivered via telehealth.
Latest:
Patient Adherence: Identifying Barriers and Defining SolutionsMajor patient and professional advocacy organizations discussed factors leading to patient nonadherence to prescription therapy and solutions for overcoming the major barriers.
Latest:
Health Care Reform's Impact on Community PharmacyThe Coalition for Community Pharmacy Action (CCPA) has been working toward ensuring that health care reform legislation favors community pharmacies-included here are some top issues and when the change will take effect.
Latest:
Biosimilar Growth in Europe Spreads to AmericaAs attention on the management of biologic agents increases, payers anticipate the first biosimilar entrant into the US market.
Latest:
Pharmacists in ACOs Part 3: Chronic Care Management, Chronic Disease State Management, and Transition of CareAfter discussing the Basics of Accountable Care Organizations and Medication Therapy Management and Annual Wellness Visit services, the third and last section of the Pharmacists in ACOs series will focus on 3 more integration strategies for pharmacists within the ACO setting, including chronic care management, chronic disease state management, and transitions of care.
Latest:
Expanding the Roles of Pharmacists: Specialty and BeyondSince 2015, there has been an increase in the number of specialty pharmacies in the United States due to their potential of handling the complexities of cost and appropriate drug access and administration.
Latest:
Costs Associated With Second-Line Therapies for Lung CancerErlotinib may confer an economic advantage for payers over docetaxel and pemetrexed for second-line treatment of lung cancer because of lower costs.
Latest:
Establishing Standards of Care for Amiodarone Monitoring in an Outpatient SettingImplementing a quality-improvement project that allows for education and interdisciplinary collaboration among pharmacists, cardiologists, and primary care providers can improve rates of amiodarone monitoring.
Latest:
Video Consults: A New Health Care EraFinding ways to help patients take their medicine as prescribed by their physician will not only help drive better health outcomes but also reduce costs.
Latest:
Joining a Pharmacy Organization Yields BenefitsGaining the most value from membership requires active participation by techs and a willingness to go outside their comfort zones.
Latest:
HIV Drug Costs Create Challenges for Patients on MedicareHIV drug prices rose 34% between 2012 and 2018 and continue to climb, which experts say is a huge issue.
Latest:
Ethical Issues in PharmacogenomicsThe clinical implementation of pharmacogenomics is an exciting area that is showing promise of enhancing the quality of patient care.
Latest:
The Role of Tyrosine Kinase Inhibitors in Non–small Cell Lung CancerThere are 5 available EGFR TKIs for the treatment of patients with EGFR-mutant lung cancers: gefitinib (Iressa), erlotinib (Tarceva), afatinib (Gilotrif), dacomitinib (Vizimpro), and osimertinib.
Latest:
Study Shows Steady Rise of Multiple Sclerosis Prevalence in United StatesThe prevalence of multiple sclerosis in the United States has steadily grown over the past 5 years to nearly 1 million people.
Latest:
Time for a Change? Looking Ahead at New Treatment Strategies for the Management of DyslipidemiaThis Continuing Education activity is supported by an educational grant from Merck Sharp & Dohme Corp.
